Teva Pharmaceuticals

Company Overview

Snapshot

Founded in January 1901, Teva Pharmaceuticals operates with over 29,000 employees. The company has raised a total of $908 million across 5 funding rounds from 5 investors. In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences.

Business overview

Teva Pharmaceuticals is a global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, the company's extensive product portfolio includes over 3,600 medicines, serving markets worldwide with approximately 120 billion tablets and capsules produced annually. Teva operates within the Health Tech & Life Sciences sector, focusing on areas such as respiratory, women's health, neurology, and oncology.

Strategic signal

In September 2025, Teva's Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy. This designation signals accelerated development and review for a drug addressing a serious condition with unmet medical needs, potentially bringing a new treatment option to patients faster and highlighting Teva's focus on specialty pharmaceuticals.

Company Intelligence Q&A

What was a significant regulatory milestone for Teva Pharmaceuticals in September 2025?

In September 2025, Teva’s Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System System Atrophy, indicating an expedited review process for this therapy.

What was a key strategic acquisition for Teva Pharmaceuticals in August 2016?

In August 2016, Teva Pharmaceuticals acquired Actavis, significantly expanding its generics portfolio.

When did Teva Pharmaceuticals go public on the NYSE?

Teva Pharmaceuticals became public on the NYSE in January 1982.